Heart failure & cardiomyopathiesRandomised controlled trial
Randomized Investigation of Heart Failure Therapy in Patients with Advanced Cancer at Risk of Cardiac Wasting: Rationale and Design of the EMPATICC Trial
- Randomised controlled trial (rationale and design)
- multicentre
- investigator-initiated
- double-blind
- proof-of-concept
- 30-day open-label extension
- Enrolment ended 30 January 2025
Authors' conclusion
EMPATICC evaluates whether HF therapy can improve function and well-being in advanced cancer, potentially reshaping care in this population.
Study context
- Population
- Stage IV solid tumours, palliative care, 1–6 month life expectancy, with CV risk and functional limitationcompleted randomization
- Participants
- 93 participants
- Comparison
- Optimized heart failure (HF) therapy plus usual care vs usual care alone
- Primary endpoint
- Hierarchical composite (win ratio): days alive and able to wash, 4 m walking ability, patient global assessment of well-being
Original publication
Randomized Investigation of Heart Failure Therapy in Patients with Advanced Cancer at Risk of Cardiac Wasting: Rationale and Design of the EMPATICC Trial. Eur J Heart Fail. Published 26 August 2025. doi:10.1002/ejhf.3799
Summarised from the published abstract; every number is checked against it